Mini Oral session 11MO - Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitorsPresentation Number11MOLecture Time08:25 - 08:30SpeakersM. Majem Tarruella (Barcelona, Spain). 31/1/2023
IMO an understated step up data release
Mini Oral session 11MO - Final data from a phase II study...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.005(1.82%) |
Mkt cap ! $407.2M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.5¢ | 27.5¢ | $99.12K | 354.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 106295 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 141296 | 9 |
View Market Depth
| Last trade - 11.00am 04/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |